Sponsors of clinical trials must submit reports of suspected unexpected serious adverse reactions to EudraVigilance, the electronic system for managing and analysing information on suspected adverse reactions to medicines in the European Economic Area (EEA).

In this section

In other sections

Sponsors should also consider the regulatory information in the sections below:

How useful do you find this page?